MDS

Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.

Advertisement
Advertisement
Melissa BadamoMyelodysplastic Syndromes | November 20, 2024
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 19, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
Melissa BadamoMyelodysplastic Syndromes | November 18, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 15, 2024
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
Jamile Shammo, MDMyelodysplastic Syndromes | November 15, 2024
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
Melissa BadamoMyelodysplastic Syndromes | November 14, 2024
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
Melissa BadamoMyelodysplastic Syndromes | November 13, 2024
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
Melissa BadamoMyelodysplastic Syndromes | November 4, 2024
More patients receiving luspatercept versus epoetin alfa saw improvements in erythroid, neutrophil, and platelet lineages.
Melissa BadamoMyelodysplastic Syndromes | November 1, 2024
More patients treated with luspatercept had improvement or resolution of neutropenia and thrombocytopenia, she said.
Jamile Shammo, MDMyelodysplastic Syndromes | October 29, 2024
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
CDC database analysis suggests that MDS-related mortality has declined since 2011, though significant disparities remain.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The COMMANDS study compared the efficacy of luspatercept with epoetin alfa in ESA-naïve lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | October 25, 2024
The researchers found a perfect correlation between the AI-based multiparametric flow cytometry score and the IPSS-M.
Melissa BadamoMyelodysplastic Syndromes | October 25, 2024
Discrepancies between the WHO and ICC classification systems for MDS can create inconsistencies in a clinical setting.
Melissa BadamoMyelodysplastic Syndromes | October 25, 2024
Through genomic profiling, researchers identified 18 MDS subtypes associated with clinical outcomes.
Valeria Santini, MDMyelodysplastic Syndromes | October 24, 2024
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | October 24, 2024
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
Jamile Shammo, MDMyelodysplastic Syndromes | October 23, 2024
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
David Swoboda, MDMyelodysplastic Syndromes | October 21, 2024
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
Jamile Shammo, MDMyelodysplastic Syndromes | October 23, 2024
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | November 6, 2024
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
Andrew MorenoMyelodysplastic Syndromes | October 4, 2024
Patients who received oral HMAs had half the mean total of health care encounter days as those who received IV or SC HMAs.
Andrew MorenoMyelodysplastic Syndromes | October 4, 2024
A TP53 variant allele frequency threshold of 24% can inform MDS prognosis equally as well as TP53 allelic status.
Andrew MorenoMyelodysplastic Syndromes | October 4, 2024
The IPSS-M significantly improved MDS prognostic assessment, particularly for high-risk IPSS-R cases.
Andrew MorenoMyelodysplastic Syndromes | October 4, 2024
In patients with lower-risk MDS receiving luspatercept, electronic medical record alerts can help improve treatment dosing.
Melissa BadamoMyelodysplastic Syndromes | September 26, 2024
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
COVID-19 infection was strongly correlated with severity, blast cell percentage, and degree of dysplasia in MDS.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
IDH1 inhibitor therapy significantly improved survival after HMA failure in patients with higher-risk MDS.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
Luspatercept yielded high rates of durable transfusion independence in heavily-pretreated, lower-risk MDS.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
Luspatercept yielded greater rates of improvement in cell lineages for patients with transfusion-dependent MDS.
Solly Chedid, MDMyelodysplastic Syndromes | October 24, 2024
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
Andrew MorenoMyelodysplastic Syndromes | September 17, 2024
Enrolled patients had non-del(5q) relapsed or refractory disease and were ineligible for erythropoiesis-stimulating agents.
Andrew MorenoMyelodysplastic Syndromes | September 13, 2024
A retrospective study's regression analysis confirmed survival effect of cytarabine-based regimens and allogeneic HSCT.
Andrew MorenoMyelodysplastic Syndromes | September 13, 2024
Inherited thrombocytopenia is associated with risk for myelodysplastic syndromes and malignancies.
Andrew MorenoMyelodysplastic Syndromes | September 13, 2024
A shorter time to response was still observed in the azacitidine plus venetoclax cohort in this retrospective study.
Melissa BadamoMyelodysplastic Syndromes | September 11, 2024
In recent studies, optical genome mapping detected additional genetic aberrations in MDS compared to conventional techniques.
Melissa BadamoMyelodysplastic Syndromes | September 26, 2024
Most patients with MDS achieved an objective response, but limited clinical activity was observed across other blood cancers.
Melissa BadamoMyelodysplastic Syndromes | September 10, 2024
The two-year cumulative incidence of relapse was lower in those who achieved full donor chimerism than in those who didn’t.
Blood Cancer TalksBlood Cancer Talks | September 5, 2024
“Blood Cancer Talks" hosts are joined by Dr. Stahl to discuss imetelstat and luspatercept treatment for lower-risk MDS.
Rebecca AraujoMyelodysplastic Syndromes | September 5, 2024
An analysis of the PEGASUS and PRINCE clinical trials reported long-term efficacy of pegcetacoplan for patients with PNH.
Rebecca AraujoMyelodysplastic Syndromes | September 5, 2024
Imetelstat led to significant improvement of red blood cell-transfusion independence rates in patients with lower-risk MDS.
Rebecca AraujoMyelodysplastic Syndromes | September 5, 2024
Combination therapies involving PD-1 and CTLA-4 inhibitors exhibited promising activity and tolerability.
Rebecca AraujoMyelodysplastic Syndromes | September 5, 2024
Treatment with luspatercept led to significantly less healthcare resource utilization compared with ESAs.
Marco Gabriele Raddi, MDMyelodysplastic Syndromes | August 19, 2024
Dr. Raddi discusses his study on identifying predictors of response to ESA therapy in patients with lower-risk MDS.
Patrick DalyMyelodysplastic Syndromes | August 14, 2024
Compared with epoetin alfa, luspatercept improved transfusion independence and hematological improvement in lower-risk MDS.
Andrew MorenoMyelodysplastic Syndromes | August 12, 2024
A study on this MDS subtype found that the allelic states of these mutations have implications for disease behavior.